Cooperative Agreement UG1CA189830

The federal Cooperative Agreement award of $946,500 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support the "KANSURVIVE 2.0" project at the University of Kansas Medical Center Research Institute, Inc. (KUMCRI). The project aims to test the effectiveness of pragmatic strategies to promote high-quality, evidence-based cancer survivorship care in rural primary care practices in Kansas. Key activities include providing education,...

This $500,000 Cooperative Agreement awarded by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) will support the establishment of the Hybrid Operations to Promote Equity (HOPE) initiative at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center. The HOPE initiative aims to address health disparities in North Carolina's diverse patient population by engaging local healthcare providers in bi-directional educational efforts and...

The National Cancer Institute (NCI) awarded a $860,545 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Miami to implement and evaluate a Comprehensive Survivorship Care (CSC) intervention in 14 Federally Qualified Health Centers (FQHCs) in South Florida. The project aims to train primary care clinicians in the CSC intervention, which integrates survivorship care plans and guidelines into the electronic medical record to improve...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a 5-year, $599,339 randomized trial to evaluate the efficacy of a multidisciplinary group-based telehealth intervention called HORIZONS. The intervention aims to improve quality of life, psychological distress, symptom burden, coping, and self-efficacy in hematopoietic stem cell transplant (HCT) survivors living with chronic graft-versus-host disease...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials for underrepresented populations, including veterans. The project aims to develop sustainable strategies to extend access and boost participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) early phase trials for...

The National Cancer Institute (NCI) awarded a $686,993 Cooperative Agreement to The Trustees of Columbia University in the City of New York under the Cancer Cause and Prevention Research (CFDA 93.393) program. The 2-year project, titled "ELECTRONIC HEALTH RECORD (EHR)-BASED IMPLEMENTATION STRATEGIES AND DECISION SUPPORT FOR HEREDITARY BREAST AND OVARIAN CANCER (HBOC) GENETIC TESTING AMONG MULTIETHNIC WOMEN (ELISABETH)", seeks to address the significant underutilization of HBOC...

This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...

This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), supports a project titled "Collaborative Oncology: Preparing for a Multisite Trial to Facilitate Communication between Radiation Oncologists and Radiologists in Cancer Treatment Planning and Surveillance". The $248,194 award to Wake Forest University Health Sciences aims to determine the feasibility and acceptability of implementing...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will fund a $334,233 research project conducted by the University of South Carolina. The project aims to examine disparities in the use of novel cancer therapies, as well as the impacts of comorbidities and multilevel factors on treatment outcomes and survival trajectories for lung and colon cancer patients, particularly among minority and rural...

The National Cancer Institute (NCI) awarded a $2,688,546 Cooperative Agreement to The Johns Hopkins University to establish the Howard-Johns Hopkins Comprehensive Alliance in Cancer Research, Education, and Equity (H2CAREE) initiative. The project, funded under the NCI's Cancer Centers Support Grants (CFDA 93.397) program, aims to advance cancer care and health equity through a partnership between Howard University and the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. The initiative...